Design and application of diabodies, triabodies and tetrabodies for cancer targeting.
暂无分享,去创建一个
H R Hoogenboom | R C Roovers | A. Kortt | P. Hudson | A. Todorovska | R. Roovers | O. Dolezal | H. Hoogenboom | P J Hudson | A A Kortt | A Todorovska | O Dolezal | Olan Dolezal | Aneta Todorovska | Rob C. Roovers | Peter J. Hudson | R. Roovers
[1] G. Winter,et al. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. , 1997, Protein engineering.
[2] M. Little,et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. , 1999, Journal of molecular biology.
[3] B. Kroesen,et al. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas , 1998, International journal of cancer.
[4] R. Souhami,et al. Chapter 1 The first international workshop on small cell lung cancer antigens , 1988 .
[5] J. Shetye,et al. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas. , 1988, Hybridoma.
[6] J. Witte,et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Hudson,et al. Recombinant antibody fragments. , 1998, Current opinion in biotechnology.
[8] L L Houston,et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. , 1993, Cancer research.
[9] T Prospero,et al. "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[10] I. Pastan,et al. Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation. , 1997, Journal of molecular biology.
[11] M. Little,et al. Bispecific CD3 × CD19 diabody for T cell‐mediated lysis of malignant human B cells , 1998 .
[12] B. Robert,et al. Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA) , 1999, International journal of cancer.
[13] J. Humm,et al. Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). , 1996, British Journal of Cancer.
[14] H. Groen,et al. Pharmacokinetics and scintigraphy of indium-111-DTPA-MOC-31 in small-cell lung carcinoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] S. Batra,et al. Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis. , 1999, Nuclear medicine and biology.
[16] R. Begent,et al. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. , 1995, Journal of immunological methods.
[17] H. Sakahara,et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. , 1999, Cancer research.
[18] D. Allen,et al. Enzyme immunoassays using bispecific diabodies. , 1997, Immunotechnology : an international journal of immunological engineering.
[19] A. Kortt,et al. High avidity scFv multimers; diabodies and triabodies. , 1999, Journal of immunological methods.
[20] H. A. Bakker,et al. Epithelial Cell Adhesion Molecule (Ep-CAM) Modulates Cell–Cell Interactions Mediated by Classic Cadherins , 1997, The Journal of cell biology.
[21] E. Kabat,et al. Sequences of proteins of immunological interest , 1991 .
[22] R. Webster,et al. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. , 1994, European journal of biochemistry.
[23] P. Hudson,et al. Synthesis of high avidity antibody fragments (scFv multimers) for cancer imaging. , 2000, Journal of immunological methods.
[24] L. Presta,et al. Remodeling domain interfaces to enhance heterodimer formation , 1997, Protein science : a publication of the Protein Society.
[25] L. Weiner. Bispecific antibodies in cancer therapy. , 1999, Cancer journal.
[26] S. Rose-John,et al. Specific targeting of cytokine-secreting cells: a bispecific diabody recognizing human interleukin-6 and CD3 induces T cell-mediated killing. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[27] Y. Li,et al. Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[28] E. Vitetta,et al. The development of monoclonal antibodies for the therapy of cancer. , 1998, Critical reviews in eukaryotic gene expression.
[29] E. Hewat,et al. Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge. , 1997, Journal of molecular biology.
[30] J. Arends,et al. High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. , 1998, British Journal of Cancer.
[31] A. Murzin,et al. The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[32] R. Kontermann,et al. Intracellular and cell surface displayed single-chain diabodies. , 1999, Journal of immunological methods.
[33] R. Hawkins,et al. The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery , 1997, Gene Therapy.
[34] P. Hudson. Recombinant antibodies: a novel approach to cancer diagnosis and therapy , 2000, Expert opinion on investigational drugs.
[35] J. L. Casey,et al. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab́ fragments , 1999, British Journal of Cancer.
[36] W G Laver,et al. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. , 1994, Structure.
[37] P. Colman,et al. Three-dimensional structures of single-chain Fv-neuraminidase complexes. , 1998, Journal of molecular biology.
[38] M. Little,et al. High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. , 1997, Journal of immunological methods.
[39] A. George,et al. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. , 1997, Journal of immunological methods.
[40] Z. Eshhar. Tumor-specific T-bodies: towards clinical application , 1997, Cancer Immunology, Immunotherapy.
[41] A. Plückthun,et al. New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.
[42] R. Williams,et al. Crystal structure of a diabody, a bivalent antibody fragment. , 1994, Structure.
[43] K. Roux,et al. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. , 1998, Journal of immunology.
[44] G. Adams,et al. Generating improved single-chain Fv molecules for tumor targeting. , 1999, Journal of immunological methods.
[45] G. Winter,et al. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). , 1995, Journal of molecular biology.
[46] P. Iliades,et al. Triabodies: single chain Fv fragments without a linker form trivalent trimers , 1997, FEBS letters.
[47] K. D. Hardman,et al. Single-chain antigen-binding proteins. , 1988, Science.
[48] R. Williams,et al. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. , 1996, Protein engineering.
[49] J. L. Casey,et al. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. , 1996, British Journal of Cancer.
[50] E. Vitetta,et al. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[51] G. Riethmüller,et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.
[52] S. Batra,et al. Effects of genetic engineering on the pharmacokinetics of antibodies. , 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[53] R. Pedley,et al. Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model. , 1993, British Journal of Cancer.
[54] Wendy S. Becker,et al. Overcoming the nephrotoxicity of radiometal‐labeled immunoconjugates , 1997, Cancer.
[55] K. Roux,et al. Flexibility of human IgG subclasses. , 1997, Journal of immunology.
[56] I. Pastan,et al. Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv. , 1998, Cancer research.
[57] S. Batra,et al. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[58] M. Little,et al. Di‐, tri‐ and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding , 1999, FEBS letters.
[59] A. Kortt,et al. ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. , 2000, Protein engineering.
[60] G. Adams,et al. Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides. , 1995, Protein engineering.
[61] P. Hudson,et al. Construction of recombinant extended single-chain antibody peptide conjugates for use in the diagnosis of HIV-1 and HIV-2. , 1996, Journal of immunological methods.
[62] Michaela A. E. Arndt,et al. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. , 1999, Blood.
[63] R. Webster,et al. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. , 1997, Protein engineering.
[64] G. Adams,et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. , 1998, British Journal of Cancer.
[65] R. Kontermann,et al. Complement recruitment using bispecific diabodies , 1997, Nature Biotechnology.
[66] V. Diehl,et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. , 1999, Cancer research.
[67] A. George,et al. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. , 1998, Journal of immunological methods.
[68] S. Litvinov,et al. The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.
[69] A. Kortt,et al. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase. , 1996, Molecular immunology.
[70] G. Riethmüller,et al. The epithelial cell surface antigen 17–1A, a target for antibody‐mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies , 1986, International journal of cancer.
[71] P. Hudson. Recombinant antibody constructs in cancer therapy. , 1999, Current opinion in immunology.
[72] A. Plückthun,et al. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. , 1998, Biochemistry.
[73] P. Iliades,et al. Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments , 1998, FEBS letters.
[74] A. Plückthun,et al. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. , 1995, Journal of molecular biology.
[75] V. Diehl,et al. CD3× anti‐nitrophenyl bispecific diabodies: Universal immunotherapeutic tools for retargeting T cells to tumors , 1999, International journal of cancer.
[76] A. Plückthun,et al. A dimeric bispecific miniantibody combines two specificities with avidity , 1998, FEBS letters.
[77] G. Walter,et al. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments , 1996, Nature Biotechnology.
[78] M. Whitlow,et al. Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. , 1994, Protein engineering.
[79] R. Bruccoleri,et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[80] A. Plückthun,et al. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. , 1998, Biochemistry.
[81] A. Kortt,et al. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. , 1999, Protein engineering.
[82] G. Winter,et al. Retargeting serum immunoglobulin with bispecific diabodies , 1997, Nature Biotechnology.
[83] G W Beresford,et al. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single‐chain antibody , 1999, International journal of cancer.
[84] R. Dillman. Monoclonal antibodies for treating cancer. , 1989, Annals of internal medicine.
[85] A. Plückthun,et al. Model and simulation of multivalent binding to fixed ligands. , 1998, Analytical biochemistry.
[86] I. Kovesdi,et al. Targeted adenovirus-mediated gene delivery to T cells via CD3 , 1997, Journal of virology.
[87] L E Williams,et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. , 1996, Immunotechnology : an international journal of immunological engineering.
[88] E. Padlan,et al. Anatomy of the antibody molecule. , 1994, Molecular immunology.
[89] L. Zardi,et al. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. , 1999, Cancer research.
[90] H. A. Bakker,et al. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule , 1994, The Journal of cell biology.